BBC 股價展望與 ETF 分析 - 配息·管理費·持股·NAV·RSI·MACD

Q: BBC 有配息嗎？

BBC 的配息殖利率約為 1.46%。

BBC

Virtus Biotech Clinical Trials ETF

收盤價 11月10日 4:00 PM ET（韓國 11/11 06:00）

$44.88

-0.11 ▼ -0.25%

11月10日 4:00 PM ET（韓國 11/11 06:00）

$44.88

+0.00 +0.00%

下降三角形阻力線 43.29 支撐線 39.07 突破阻力連續7天同一條線

AI 繪製的圖表形態僅供參考。

詳細指標表

Category ⓘ	US Equities - Industry Sector	Expense ⓘ	0.65%	Return% 1Y ⓘ	52.36%	Total Holdings ⓘ	130	Perf Week ⓘ	4.84%	Volume ⓘ	54,143
Asset Type ⓘ	Equities (Stocks)	AUM ⓘ	$32M	Return% 3Y ⓘ	36.17%	NAV ⓘ	$45.10	Perf Month ⓘ	4.23%	Avg Volume ⓘ	0.03M
ETF Type ⓘ	US Equities	Dividend TTM ⓘ	$0.66 (1.46%)	Return% 5Y ⓘ	0.2%	52W High ⓘ	-20.11%	Perf Quarter ⓘ	-15.41%	Rel Volume ⓘ	1.79
Active/Passive ⓘ	Passive	Div Gr. 3/5Y ⓘ	-	Return% 10Y ⓘ	9.83%	52W Low ⓘ	47.29%	Perf Half Y ⓘ	0.76%	Prev Close ⓘ	$44.99
IPO ⓘ	2014/12/17	Flows% 1M ⓘ	-24.91%	Return% SI ⓘ	4.89%	RSI (14) ⓘ	54.47	Perf YTD ⓘ	16.39%	Price ⓘ	$44.88
Beta ⓘ	0.94	Flows% 3M ⓘ	-24.91%	Flows% YTD ⓘ	-15.61%	Flows% 1Y ⓘ	5.84%	Perf Year ⓘ	45.53%	Volatility(W/M) ⓘ	4.93% 3.71%
SMA20 ⓘ	6.06%	SMA50 ⓘ	-1.35%	SMA200 ⓘ	-1.76%	ATR ⓘ	1.7

ETF 簡介

Virtus Biotech Clinical Trials ETFBBC | NYSE | 醫療類股查看深度分析

Virtus LifeSci Biotech Clinical Trials ETF seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

BBC ETF 一覽

0.65% 越低越好

$32M 管理資產

130檔

1.46%

掛牌日 2014年

管理方式追蹤指數

發行公司 Virtus

主要持有標的持有 130 檔

前 10 大持股占 基金的 14%

均勻分散在眾多持股中。